Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model

Biomaterials

Volumn 33, Issue 23, 2012, Pages 5768-5775

  Masi, Byron C ^a,b   Tyler, Betty M ^c   Bow, Hansen ^c   Wicks, Robert T ^c   Xue, Yuan ^b   Brem, Henry ^c   Langer, Robert ^a,b   Cima, Michael J ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Glioma; Localized delivery; MEMS; Microchip; Temozolomide

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN TUMORS; CYTOTOXIC; DRUG-RELEASE RATE; GLIOMA; GLIOSARCOMA; HIGH CONCENTRATION; IN-VITRO; IN-VIVO; LOCALIZED DELIVERY; MEDIAN SURVIVAL; MICROCHIP; NITRIDE MEMBRANES; RELEASE KINETICS; TEMOZOLOMIDE; TEMPORAL CONTROLS;

ANIMALS; BRAIN; DISEASE CONTROL; DRUG DELIVERY; KINETICS; MEMS; MICROPROCESSOR CHIPS; NITRIDES; TUMORS;

DISEASES;

TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DEVICE SAFETY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FEMALE; GLIOSARCOMA; IMMUNOHISTOLOGY; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MICROELECTROMECHANICAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; GLIOSARCOMA; RATS; RATS, INBRED F344;

ANIMALIA; RATTUS; RODENTIA;

EID: 84861339216     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.048     Document Type: Article

References (36)

1. Deorah S., Lynch C.F., Sibenaller Z., Ryken T.C. Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 2006, 20(4):E1. 1-7.
2. Hou L.C., Veeravagu A., Hsu A.R., Tse V.C.K. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006, 20(4):E3. 1-9.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005, 352(10):987-996.
4. Pardridge W.M. Drug delivery to the brain. J Cerebr Blood F Met 1997, 17(7):713-731.
5. Groothuis D.R., Benalcazar H., Allen C.V., Wise R.M., Dills C., Dobrescu C., et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res Int 2000, 856:281-290.
6. Lidar Z., Mardor Y., Jonas T., Pfeffer R., Faibel M., Nass D., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004, 100:472-479.
7. Sawyer A.J., Piepmeier J.M., Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006, 79:141-152.
8. Sampson J.H., Akabani G., Friedman A.H., Bigner D., Kunwar S., Berger M., et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006, 20(4):E14. 1-4.
9. Raghavan R., Brady M.L., Rodríguez-Ponce M.I., Hartlep A., Pedain C., Sampson J.H. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006, 20(4):E12.
10. Kawakami K., Kawakami M., Kioi M., Husain S.R., Puri R.K. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004, 101:1004-1011.
11. Brem S., Tyler B., Li K., Pradilla G., Legnani F., Caplan J., et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Canc Chemother Pharmacol 2007, 60(5):643-650.
12. Guerin C., Olivi A., Weingart J.D., Lawson H.C., Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drug 2004, 22(1):27-37.
13. Tyler B., Fowers K.D., Li K.W., Recinos V.R., Caplan J.M., Hdeib A., et al. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg 2010, 113(2):210-217.
14. Lesniak M.S., Upadhyay U., Goodwin R., Tyler B., Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005, 25(6B):3825-3831.
15. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003, 5(2):79-88.
16. Valtonen S., Timonen U., Toivanen P., Kalimo H., Kivipelto L., Heiskanen O., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41(1):44-48. discussion 8-9.
17. Lesniak M.S., Brem H. Targeted therapy for brain tumours. Nat Rev Drug Discov 2004, 3(6):499-508.
18. McGirt M.J., Than K.D., Weingart J.D., Chaichana K.L., Attenello F.J., Olivi A., et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009, 110(3):583-588.
19. Scott A.W., Tyler B.M., Masi B.C., Upadhyay U.M., Patta Y.R., Grossman R., et al. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials 2011, 32(10):2532-2539.
20. Pradilla G., Wang P.P., Gabikian P., Li K., Magee C.A., Walter K.A., et al. Local intracerebral administration of paclitaxel with the paclimer delivery system: toxicity study in a canine model. J Neuro Oncol 2006, 76(2):131-138.
21. Maloney J.M., Uhland S.A., Polito B.F., Sheppard N.F., Pelta C.M., Santini J.T. Electrothermally activated microchips for implantable drug delivery and biosensing. J Control Release 2005, 109:244-255.
22. Prescott J.H., Lipka S., Baldwin S., Sheppard N.F., Maloney J.M., Coppeta J., et al. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006, 24(4):437-438.
23. Santini J.T., Cima M.J., Langer R. A controlled-release microchip. Nat Biotechnol 1999, 397:335-338.
24. Santini J.T., Richards A.C., Scheidt R., Cima M.J., Langer R. Microchips as controlled drug-delivery devices. Angew Chem Int Ed 2000, 39:2396-2407.
25. Santini J.T., Richards A.C., Scheidt R.A., Cima M.J., Langer R.S. Microchip technology in drug delivery. Ann Med 2000, 32(6):377-379.
26. Elman N.M., Patta Y., Scott A.W., Masi B., Ho Duc H.L., Cima M.J. The next generation of drug-delivery microdevices. Clin Pharmacol Ther 2009, 85(5):544-547.
27. Elman N.M., Upadhyay U.M. Medical applications of implantable drug delivery microdevices based on MEMS (micro-electro-mechanical-systems). Curr Pharmaceut Biotechnol 2010, 11(4):398-403.
28. Cima M.J. Microsystem technologies for medical applications. Annu Rev Chem Biomol Eng 2011, 2(1):355-378.
29. Li Y., Ho Duc H.L., Tyler B., Williams T., Tupper M., Langer R., et al. In vivo delivery of BCNU from a MEMS device to a tumor model. J Control Release 2005, 106:138-145.
30. Li Y., Shawgo R.S., Tyler B., Henderson P.T., Vogel J.S., Rosenberg A., et al. In vivo release from a drug delivery MEMS device. J Control Release 2004, 100:211-219.
31. Elman N.M., Ho Duc H.L., Cima M.J. An implantable MEMS drug delivery device for rapid delivery in ambulatory emergency care. Biomed Microdevices 2009, 11(3):625-631.
32. Farra R., Sheppard N.F., McCabe L., Neer R.M., Anderson J.M., Santini J.T., et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med 2012, 4(122):122ra21.
33. Kim H.K., Lin C.-C., Parker D., Veals J., Lim J., Likhari P., et al. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active products of the antitumor agent temozolomide, in human plasma. J Chrom B 1997, 703:225-233.
34. Elman N.M., Masi B.C., Cima M.J., Langer R. Electro-thermally induced structural failure actuator (ETISFA) for implantable controlled drug delivery devices based on micro-electro-mechanical-systems. Lab Chip 2010, 10(20):2796-2804.
35. Newlands E.S., Stevens M.F.G., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Canc Treat Rev 1997, 23:35-61.
36. Xue Y., Lim S., Yang Y., Wang Z., Jensen L.D., Hedlund E.M., et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2011, 18(1):100-110.